טוען...
Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives
Low-density lipoprotein lowering with statins has convincingly and consistently proven to reduce cardiovascular events in both primary and secondary prevention. However, despite high-dose statin therapy, residual cardiovascular risk remains and many patients also do not tolerate statins. Ezetimibe w...
שמור ב:
| הוצא לאור ב: | Cardiol Res Pract |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Hindawi
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7338976/ https://ncbi.nlm.nih.gov/pubmed/32670636 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/9815016 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|